Omeros Corporation (OMER)

NGM – Цена в реальном времени. Валюта: USD

14.76

+0.40 (2.79%)

При закрытии: May 12, 2026, 4:00 PM EDT

14.94

+0.18 (1.22%)

До открытия: May 13, 2026, 4:22 AM EDT

11.05.2026

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will issue its financial results for the first quarter 2026 on Wednesday, May 13, 2026 after market close. Omeros management will host a conference call and webcast that same day at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) to discuss recent developments and highlights as well as the Company's financial results. Conference Call Details and Webcast Link Instructions To access the live webcast, please click.

27.04.2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Does Omeros (OMER) have what it takes to be a top stock pick for momentum investors? Let's find out.

27.04.2026

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

The consensus price target hints at a 222.8% upside potential for Omeros (OMER). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

27.04.2026

4 Medical Product Stocks to Buy From a Challenging Industry

The Zacks Medical - Products industry faces macro headwinds, keeping growth under pressure in 2026, but steady demand may continue. PAHC, BLFS, OMER and BWAY reflect the favorable fundamentals.

16.04.2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has assigned a permanent Healthcare Common Procedure Coding System (HCPCS) J-code for YARTEMLEA®. The J-code for YARTEMLEA (J1289) simplifies and streamlines billing and reimbursement for patients covered by U.S. government programs (e.g., Medicare) and commercial payers. The J-code will become effective July 1, 2026. “For patients with TA-TMA, access to e.

10.04.2026

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

The average of price targets set by Wall Street analysts indicates a potential upside of 266.7% in Omeros (OMER). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

02.04.2026

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Omeros Corporation maintains a Buy rating, driven by Yartemlea's FDA approval for TA-TMA and the Novo Nordisk zaltenibart deal. OMER's 2025 net loss narrowed to $(3.35m) due to a $237.6m gain on zaltenibart rights; cash position improved and debt reduced by 47%. Yartemlea, priced at $36k per vial, targets a potential $5.4bn TAM with first-mover advantage, but faces potential pricing and competitive risks as Soliris generics emerge.

Видео

No Data

There is no data to display

Пресс-релизы

16.04.2026

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

31.03.2026

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (Nasdaq: OMER) today announced recent highlights and developments as well as financial results for the fourth quarter and year ended December 31, 2025, which include: Net income for the fourth quarter of 2025 was $86.5 million, or $1.22 per share, compared to a net loss of $31.4 million, or $0.54 per share, for the fourth quarter of 2024. For the year ended December 31, 2025, net loss was $3.4 million, or $0.05 per share, compared to a net loss of $1.

21.03.2026

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced that it will host an industry session at the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) on March 22, 2026, from 2:30pm - 4pm CET in Madrid, Spain. The session, titled “Advances in TA-TMA Treatment: Evaluating the Role of a Novel Targeted Therapy,” will be co-chaired by Rafael Duarte, MD, PhD, Hospital Universitario Puerta de Hierro Majadahonda, and Mohamad Mohty, MD, PhD, Hôp.

17.02.2026

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

SEATTLE--(BUSINESS WIRE)--Omeros Corporation (NASDAQ: OMER) today announced the successful completion of its initial study in nonhuman primates evaluating the efficacy and safety of its OncotoX-AML cancer therapeutic platform. Omeros' OncotoX-AML therapeutic is first targeting acute myeloid leukemia (AML), an aggressive and highly fatal bone marrow and blood cancer. The effectiveness of current AML treatments, such as chemotherapeutics and antibody-drug conjugates, are limited by substantial si.

Omeros Corporation (OMER)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Omeros Corporation (OMER)

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

4 Medical Product Stocks to Buy From a Challenging Industry

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Видео

No Data

Пресс-релизы

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

4 Medical Product Stocks to Buy From a Challenging Industry

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Видео

No Data

Пресс-релизы

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Search stocks

Omeros Corporation (OMER)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Omeros Corporation (OMER)

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

4 Medical Product Stocks to Buy From a Challenging Industry

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Видео

No Data

Пресс-релизы

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program

Omeros Corporation to Announce First Quarter Financial Results on May 13, 2026

Here's Why Omeros (OMER) is a Great Momentum Stock to Buy

Wall Street Analysts Believe Omeros (OMER) Could Rally 222.76%: Here's is How to Trade

4 Medical Product Stocks to Buy From a Challenging Industry

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Does Omeros (OMER) Have the Potential to Rally 266.67% as Wall Street Analysts Expect?

Omeros: Making The Bull Case On Q4 Earnings, Ahead Of Key Q1 Commercial Updates

Видео

No Data

Пресс-релизы

CMS Assigns Permanent Reimbursement J-Code for YARTEMLEA® (narsoplimab-wuug)

Omeros Corporation Reports Fourth Quarter and Year-End 2025 Financial Results

Omeros Announces Upcoming Presentation at EBMT 2026 Highlighting Advances in TA-TMA Treatment

Omeros Announces Successful Primate Study in OncotoX-AML™ Drug Program